Skip to main content

Table 1 Baseline characteristics by diabetes mellitus status and ever use of glucocorticoids during follow-up (N = 9085)

From: The effect of glucocorticoid therapy on mortality in patients with rheumatoid arthritis and concomitant type II diabetes: a retrospective cohort study

  DM at baseline No DM at baseline DM during FUa
All subjects Never users Ever users All subjects Never users Ever users All subjects Never users Ever users
N = 1034 N = 512 N = 522 N = 8051 N = 4026 N = 4025 N = 761 N = 269 N = 492
Females, n (%) 652 (63.1) 325 (63.5) 327 (62.6) 5600 (69.6) 2878 (71.5) 2722 (67.6) 503 (66.1) 176 (65.4) 327 (66.5)
Age at baseline (years), mean (standard deviation (SD)) 64.42 (13.0) 63 13.6) 65.81 (12.3) 58.51 (14.7) 55.94 (14.6) 61.07 (14.4) 64.63 (12.8) 62.4 (12.9) 65.86 (12.5)
Body Mass Index in year prior to baseline
 mean (SD) 29.77 (6.5) 29.78 (6.7) 29.77 (6.3) 27.14 (5.5) 27.17 (5.5) 27.1 (5.4) 29.86 (6.9) 30.71 (6.8) 29.35 (6.9)
 Missing (%) 180 (17.4) 87 (17.0) 93 (17.8) 3669 (45.6) 1853 (46.0) 1816 (45.1) 224 (29.4) 68 (25.3) 156 (31.7)
Smoking status at baseline, n (%)
 Never smoker 407 (39.4) 203 (39.7) 204 (39.1) 3337 (41.5) 1748 (43.4) 1589 (39.5) 234 (30.8) 80 (29.7) 154 (31.3)
 Ever smoker 600 (58.0) 293 (57.2) 307 (58.8) 3988 (49.5) 1949 (48.4) 2039 (50.7) 505 (66.4) 182 (67.7) 323 (65.7)
 Missing 2 (0.2) 1 (0.2) 1 (0.2) 41 (0.5) 20 (0.5) 21 (0.5) 5 (0.7) 1 (0.4) 4 (0.8)
SES quintile at baseline (In subset), n (%)
 First (least deprived) 214 (20.7) 102 (19.9) 112 (21.5) 1830 (22.7) 910 (22.6) 920 (22.9) 165 (21.7) 60 (22.3) 105 (21.3)
 Second 224 (21.7) 98 (19.1) 126 (24.1) 1993 (24.8) 1023 (25.4) 970 (24.1) 182 (23.9) 65 (24.2) 117 (23.8)
 Third 215 (20.8) 121 (23.6) 94 (18.0) 1731 (21.5) 839 (20.8) 892 (22.2) 156 (20.5) 62 (23.1) 94 (19.1)
 Fourth 229 (22.2) 119 (23.2) 110 (21.1) 1470 (18.3) 741 (18.4) 729 (18.1) 161 (21.2) 49 (18.2) 112 (22.8)
 Fifth (most deprived) 150 (14.5) 71 (13.9) 79 (15.1) 986 (12.3) 493 (12.3) 493 (12.3) 92 (12.1) 32 (11.9) 60 (12.2)
 Missing 2 (0.2) 1 (0.2) 1 (0.2) 41 (0.5) 20 (0.5) 21 (0.5) 6 (0.8) 1 (0.4) 5 (1.0)
Charlson comorbidity index at baseline, mean (SD) 2.57 (0.8) 2.48 (0.8) 2.66 (0.8) 1.32 (0.7) 1.23 (0.6) 1.42 (0.7) 2.63 (0.8) 2.39 (0.7) 2.76 (0.8)
Prior history of macrovascular diseases, n (%) 113 (10.9) 41 (8.0) 72 (13.8) 297 (3.7) 108 (2.7) 189 (4.7) 77 (10.1) 16 (6.0) 61 (12.4)
History of GC use in year prior to baseline, n (%) 325 (31.4) 42 (8.2) 283 (54.2) 1861 (23.1) 256 (6.4) 1605 (39.9) 299 (39.3) 3 (1.1) 296 (60.2)
Duration of diabetes at baseline (yrs)
 Mean (SD) 4.59 (3.7) 4.88 (3.8) 4.31 (3.6) N/A N/A N/A N/A N/A N/A
Number of anti-DM medication prior to baseline
 0 525 (50.8) 264 (50.6) 261 (51.0) N/A N/A N/A N/A N/A N/A
 1 482 (46.6) 249 (47.7) 233 (45.5) N/A N/A N/A N/A N/A N/A
 2 26 (2.5) 8 (1.5) 18 (3.5) N/A N/A N/A N/A N/A N/A
 3 1 (0.1) 1 (0.2) 0 (0) N/A N/A N/A N/A N/A N/A
Prescribed insulin prior to follow-up, n (%) 155 (15.0) 86 (16.8) 69 (13.2) N/A N/A N/A N/A N/A N/A
DMARDs prescribed during follow-up, n (%)
 Methotrexate 633 (61.2) 309 (60.4) 324 (62.1) 5012 (62.3) 2386 (59.3) 2626 (65.2) 353 (46.4) 110 (40.9) 243 (49.4)
 Hydroxychloroquine 261 (25.2) 132 (25.8) 129 (24.7) 2304 (28.6) 1129 (28.0) 1175 (29.2) 138 (18.1) 49 (18.2) 89 (18.1)
 Sulfasalazine 372 (36.0) 171 (33.4) 201 (38.5) 3333 (41.4) 1591 (39.5) 1742 (43.3) 207 (27.2) 80 (29.7) 127 (25.8)
 Leflunomide 75 (7.3) 28 (5.5) 47 (9.0) 719 (8.9) 264 (6.6) 455 (11.3) 57 (7.5) 13 (4.8) 44 (8.9)
 Other 70 (6.8) 15 (2.9) 55 (10.5) 549 (6.8) 117 (2.9) 432 (10.7) 54 (7.1) 6 (2.2) 48 (9.8)
Average GC dose during follow up, mean (SD) 4.93 (14.0) 0 9.8 (18.5) 4.38 (6.3) 0 8.75 (6.4) 5.02 (6.3) 0 7.77 (6.4)
  1. aCharacteristics at time of diabetes mellitus diagnosis